drugset / Trial / NCT02221869

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

NCT02221869

Phase 3 Completed 106 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to assess the efficacy and safety of Xyrem in pediatrics subjects with narcolepsy that includes cataplexy.

Timeline

Start
2014-10-01
Primary completion
2017-02
Completion
2019-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Oxybate Unknown 9 g Oral